➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Harvard Business School
Mallinckrodt
AstraZeneca
McKesson

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Amgen Inc. v. Ariad Pharmaceuticals Inc. (D. Del. 2006)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Amgen Inc. v. Ariad Pharmaceuticals Inc. (D. Del. 2006)

Docket   Start Trial Date Filed 2006-04-20
Court District Court, D. Delaware Date Terminated 2010-01-04
Cause 28:2201 Declaratory Judgment Assigned To Judge Mary Pat Thynge
Jury Demand Defendant Referred To
Parties AMGEN INC.; AMGEN MANUFACTURING LIMITED; AMGEN USA INC.; ARIAD PHARMACEUTICALS INC.; IMMUNEX CORPORATION; IMMUNEX RHODE ISLAND CORPORATION; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH; WYETH
Patents 3,959,322; 4,418,068; 4,737,462; 5,393,763; 5,457,117; 5,756,349; 6,248,741; 6,465,464; 6,599,873; 8,080,580; 9,056,051
Attorneys Amir A. Naini; Anne Shea Gaza; Charles E. Lipsey; Christopher M. Newman; David I. Gindler; Elizabeth L. Rosenblatt; Frederick L. Cottrell , III; Howard W. Levine; John G. Day; Lauren E. Maguire; Mary Frances Dugan; Melanie K. Sharp; Morgan Chu; Richard M. Birnholz; Robert C. Stanley; Robert D. Bajefsky; Steven J. Balick; Tiffany Geyer Lydon; Wendy A. Whiteford
Link to Docket External link to docket
Small Molecule Drugs cited in Amgen Inc. v. Ariad Pharmaceuticals Inc.
Biologic Drugs cited in Amgen Inc. v. Ariad Pharmaceuticals Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Amgen Inc. v. Ariad Pharmaceuticals Inc. (D. Del. 2006)

Date Filed Document No. Description Snippet Link To Document
2007-03-05 152 Notice to Take Deposition ) described and claimed in U.S. Patents No. 5,075,222 and/or 6,599,873. 8. The nature, existence and …prior art to the ’516 PATENT. D. “’516 PATENT” shall mean United States Patent No. 6,410,516 entitled… ’516 PATENT is invalid for, among other things, failing to meet the requirements of the Patent Laws of…invention before the patent applicants 5. AMGEN’s contention that any claim of the ’516 PATENT is invalid for…OF TESTIMONY 1. AMGEN’s contention that the ’516 PATENT is invalid, including the basis for AMGEN’s assertions External link to document
2007-04-04 175 Objections ) described and claimed in U.S. Patents No. 5,075,222 and/or 6,599,873. RESPONSE: The Amgen Entities… ’516 PATENT is invalid for, among other things, failing to meet the requirements of the Patent Laws of…)NY NO. 1: Al\/IGEN’s contention that the ’516 PATENT is invalid, including the basis for AMGEN’s assertions…render invalid any one or more claims of the ’516 PATENT, including but not limited to PRIGR ART that AMGEN…invalid any one or more claims of the "516 PATENT under 35 U.S.C. § lOZ(a), 35 U.S.C. § (b) [sic] External link to document
2007-05-16 247 Notice (Other) /or claimed in U.S. Patent Nos. 5,075,222; 6,599,873; and/or any patents or patent applications that claim… prosecution of U.S. Patent Nos. 5,075,222; 6,599,873; and any patents or patent applications that claim…subject matter described in U.S. Patent Nos. 5,075,222 and/or 6,599,873. REQUEST NO. 7: All DOCUMENTS…tumor necrosis factor. M. “’516 PATENT” shall mean United States Patent No. 6,410,516 entitled “Nuclear…US 6,410,516 Bl Jun. 25, 2002 (10) Patent No.: (45) Date of Patent: (54) (75) (73) (*) (21) (22 External link to document
2007-05-16 248 Notice (Other) /or claimed in U.S. Patent Nos. 5,075,222; 6,599,873; and/or any patents or patent applications that claim… prosecution of U.S. Patent Nos. 5,075,222; 6,599,873; and any patents or patent applications that claim…subject matter described in U.S. Patent Nos. 5,075,222 and/or 6,599,873. REQUES'I` NO. 7: All DOCUMENTS…tumor necrosis factor. M. “’516 PATENT” shall mean United States Patent No. 6,410,516 entitled “Nuclear…United States Patent Baltimore et al. Filed 05/16/2007_*'1-"age 9 of 51 (10) Patent No.: (45) External link to document
2007-07-02 351 Redacted Document Press, 1981); and U,S, Pat Nos` 4,518,534 and 4,737,462 disclose suitable tech.uicplesl and arc incorporated…| United States Patent nn S!nith et al. Filed 07/02/2007 Usoo§ass‘!ecA {11] Patent Number: 5,395,760… as Exhibit A is a true and correct copy ofU,S, Patent No. 5,395,760. 4n Attached he:‘eto as Exhibit B…5,395,760 §45] Date of Patent: Mar. 7, 1995 [5¢] DNA ENCODING TU'MOR NECROSIS FACTOR-cz AND ~B RECEPTDRS…00259-|\/|PT Document351-2 Filed 07/02/2007 U.S. Patent Mar. 7, 1995 chest 3 era Figure 213 CAG GTG AAA External link to document
2007-08-10 379 Letter 28, 35, and 36 of U.S. Patent 3,959,322 is not restricted say suggest the subject …none of these four patents patent, the '909 patent or the '714 patent would not have can…'911 patent. All patents are '322 patent as well as the claims of the '911 patent to the …of the 525 patent approval. The patented method is analogous to a reads: patent on a microscope… of drugs from patent infringement suits. '567 patent (the “ '567 Patent”) and that the External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Baxter
Mallinckrodt
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.